Medication info
Lyrica Capsule 50 mg (Pregabalin)

Lyrica Capsule 50 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Viatris
Appearance
A white capsule with a white upper part and a black line, containing a white or light yellow powder.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201800929 · Approved 2018.02.26 · Insurance code 073400240

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is eliminated primarily by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. This medicine is administered at an initial dose of 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is eliminated primarily by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Importer
Viatris

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in adults with epilepsy. Additionally, it helps in the treatment of fibromyalgia. It is effective in improving symptoms of major neuropathic pain, some epileptic seizures, and myalgia.

How to take

Adult dose

This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is eliminated primarily by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. This medicine is administered at an initial dose of 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, the dose may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is eliminated primarily by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalinᵃ Administration method Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single doseᵇ TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: Supplemental dose refers to a dose administered once as an additional dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so careful observation for mood changes or unusual behaviors should be conducted during treatment. Patients allergic to any ingredients in this medication or those with certain genetic lactose intolerance should not take it. Diabetic patients should be cautious as weight gain after taking this medication may require adjustments in their blood glucose control medications. If allergic reactions like angioedema occur, discontinue use immediately and consult medical personnel. Elderly patients should be careful as this medication may increase dizziness or drowsiness, leading to a higher risk of falls or accidents. Blurred vision or changes in vision may occur during treatment; if symptoms persist, consult a doctor. Sudden discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually under medical supervision. Patients with a history of drug abuse should take special care as this medication carries a risk of abuse. Patients with impaired renal function may require dosage adjustments for this medication. Patients with heart diseases should proceed carefully as there may be a risk of congestive heart failure when taking this medication. Taking this medication with central nervous system depressants may increase the risk of drowsiness or respiratory depression, so caution is advised. In early pregnancy, there is a risk of fetal malformation, so this medication should be avoided during pregnancy, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing this medication as it may be excreted in breast milk. Dizziness and drowsiness may occur during treatment; therefore, driving or operating dangerous machinery should be avoided until symptoms are assessed. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be necessary if needed. This medication should be kept out of reach of children, and transferring to another container should be avoided.

Side effects

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, swelling around the mouth, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, thoughts of suicide, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory suppression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, feeling of well-being, decreased libido, depersonalization, sexual sensation disorder, restlessness, anxiety, mood swings, emotional decline, emotional elevation, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, dizziness, drowsiness, ataxia, motor coordination disorders, balance disorders, amnesia, attention disorders, memory disorders, tremors, speech disorders, sensory abnormalities, sensory reduction, sedation, hypersomnia, cognitive disorders, nystagmus, language disorders, focal dystonia, decreased reflexes, motor abnormalities, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, tremor at rest, syncope, confusion, psychomotor retardation, olfactory abnormalities, loss of taste, handwriting difficulty, blurred vision, diplopia, loss of peripheral vision, visual impairment, visual field loss, photophobia, dry eyes, eye swelling, reduced vision, eye pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, changes in depth perception during vibration, strabismus, bright vision, vertigo, hyperacusis, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory suppression, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, excessive salivation, gastroesophageal reflux disease, reduced oral sensation, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, sensory disturbances, fatigue, chest tightness, systemic edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase levels, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium levels, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, shock, anaphylaxis-like symptoms, skin and mucous membrane syndrome, erythema multiforme, delirium, paralysis, affective disorders, drowsiness, confusion, depression, agitation, restlessness, worsening of seizures, gastrointestinal disorder, tinnitus, sleep disorders, skin diseases, increased BUN, bloody stools

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A white capsule with a white upper part and a black line, containing a white or light yellow powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.